Shi, Patricia, M.D. — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications5liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
PlerixaforThe purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.	Cancer	NA	Thérapie cellulaire	United States	À vérifier
PlerixaforThe purpose of this study is to determine whether it is safe and effective to collect peripheral blood hematopoietic stem cells 16 hours rather than the usual 11 hours after administration of plerixafor.	Cancer	NA	Thérapie cellulaire	United States	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
Plerixafor	Cancer	NA	NCT01042717	Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection	UNKNOWN

Publications

5

Molécule	Indication / population	Titre	Journal	Date
Plerixafor		Effects of Stromal Cell-Derived Factor 1 on Osteoblast Activity During Orthodontic Tooth Movement.	Clinical and experimental dental research
Plerixafor		PAMD-Ch17, a Polymeric Analog of Plerixafor, Induces Mitochondrial Dysfunction in T-ALL Cells Independent of CXCR4.	Molecular cancer therapeutics
Plerixafor		CXCR4 coordinates adhesion, migration, and development of human NK cells.	JCI insight
Plerixafor		Pharmacological Strategies for Mitigating Cytarabine-Induced Multi-Organ Toxicity: A Scoping Review on Mechanisms, Efficacy and Clinical Implications.	Cancers
Plerixafor		Non-cryopreserved hematopoietic stem cell transplantation compared to conventional autologous peripheral stem cell transplantation with cryopreserved stem cells among patients newly diagnosed with myeloma.	Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis